DK1233770T3 - Phosphonatforbindelser - Google Patents

Phosphonatforbindelser

Info

Publication number
DK1233770T3
DK1233770T3 DK00982468T DK00982468T DK1233770T3 DK 1233770 T3 DK1233770 T3 DK 1233770T3 DK 00982468 T DK00982468 T DK 00982468T DK 00982468 T DK00982468 T DK 00982468T DK 1233770 T3 DK1233770 T3 DK 1233770T3
Authority
DK
Denmark
Prior art keywords
phosphonate
disorders
osteoporosis
cancer
treating
Prior art date
Application number
DK00982468T
Other languages
English (en)
Inventor
James R Beadle
Karl Y Hostetler
Ganesh D Kini
Original Assignee
Univ California At San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California At San Diego filed Critical Univ California At San Diego
Application granted granted Critical
Publication of DK1233770T3 publication Critical patent/DK1233770T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/404—Esters of poly(thio)phosphonic acids containing hydroxy substituents in the hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids R—P(OH)2; Thiophosphonous acids including RHP(=O)(OH); Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
DK00982468T 1999-12-03 2000-12-04 Phosphonatforbindelser DK1233770T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16881399P 1999-12-03 1999-12-03
US20571900P 2000-05-19 2000-05-19
PCT/US2000/033079 WO2001039724A2 (en) 1999-12-03 2000-12-04 Phosphonate compounds

Publications (1)

Publication Number Publication Date
DK1233770T3 true DK1233770T3 (da) 2008-06-16

Family

ID=26864475

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08001408.7T DK1914237T3 (da) 1999-12-03 2000-12-04 Antivirale fosfonatesterforbindelser
DK00982468T DK1233770T3 (da) 1999-12-03 2000-12-04 Phosphonatforbindelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08001408.7T DK1914237T3 (da) 1999-12-03 2000-12-04 Antivirale fosfonatesterforbindelser

Country Status (18)

Country Link
US (14) US6716825B2 (da)
EP (1) EP1233770B1 (da)
JP (4) JP4993649B2 (da)
KR (1) KR20020073342A (da)
CN (1) CN1414854B (da)
AT (1) ATE385797T1 (da)
AU (3) AU785355B2 (da)
BR (1) BR0016058A (da)
CA (2) CA2747954C (da)
CY (1) CY1107927T1 (da)
DE (1) DE60038038T2 (da)
DK (2) DK1914237T3 (da)
ES (2) ES2300281T3 (da)
HK (1) HK1050627B (da)
MX (1) MXPA02005490A (da)
PT (2) PT1914237E (da)
RU (1) RU2258707C2 (da)
WO (1) WO2001039724A2 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
CA2451881A1 (fr) * 2001-07-16 2003-01-30 Universite Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
FR2837490B1 (fr) * 2002-03-21 2009-04-17 Univ Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
WO2003075884A1 (en) * 2002-03-06 2003-09-18 Lifizz, Inc. Effervescent compositions comprising bisphosphonates and methods related thereto
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EA200401437A1 (ru) * 2002-04-26 2005-04-28 Джилид Сайэнс, Инк. Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
DK1628685T3 (da) 2003-04-25 2011-03-21 Gilead Sciences Inc Antivirale phosphonatanaloge
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
JP2006524710A (ja) 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
AU2004290298A1 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005044308A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
JP4692283B2 (ja) * 2003-12-12 2011-06-01 アステラス製薬株式会社 悪性黒色腫治療剤
US20080287471A1 (en) 2003-12-22 2008-11-20 Maria Fardis 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2006076015A2 (en) * 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof
HUE043207T2 (hu) 2004-07-27 2019-08-28 Gilead Sciences Inc HIV-gátló vegyületek foszfonát analógjai
NZ554783A (en) * 2004-11-15 2010-12-24 Ceptyr Inc Protein tyrosine phosphatase inhibitors and methods of use thereof
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060219637A1 (en) * 2005-03-29 2006-10-05 Killeen Kevin P Devices, systems and methods for liquid chromatography
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1868628B1 (en) * 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US20070003608A1 (en) * 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2006114065A2 (en) * 2005-04-25 2006-11-02 Institute Of Organic Chemistry And Biochemistry A Cademy Of Sciences Of The Czech Republic Use of compounds to inhibit neoplasia
US7914810B2 (en) 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
US8114843B2 (en) 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
EP2012799B1 (en) * 2006-05-03 2016-08-24 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
MX2009011573A (es) * 2007-04-27 2010-01-20 Chimerix Inc Metodos de reduccion de nefrotoxicidad en sujetos administrados con nucleosido.
EP2234623A4 (en) * 2007-12-27 2012-03-28 Epiphany Biosciences ANTIVIRAL CONNECTIONS
JP5562255B2 (ja) 2008-01-25 2014-07-30 キメリクス，インコーポレイテッド ウイルス感染を治療する方法
US20100093667A1 (en) 2008-07-08 2010-04-15 Gilead Sciences, Inc. Salts of hiv inhibitor compounds
US8628812B2 (en) * 2008-12-30 2014-01-14 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011005510A2 (en) * 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011017253A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CA2775004A1 (en) * 2009-10-02 2011-04-07 Straitmark Holding Ag Method for the manufacture of aminohydroxy diphosphonic acids
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
WO2011130557A2 (en) 2010-04-14 2011-10-20 The Regents Of The University Of California Phosphonates with reduced toxicity for treatment of viral infections
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
CN103209985B (zh) 2010-08-31 2016-08-24 奇默里克斯公司 膦酸酯衍生物及其合成方法
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
CN103945869A (zh) * 2011-08-31 2014-07-23 马林克罗特有限公司 使用h-膦酸酯-烯/-炔的氢膦酸酯化反应进行的靶向纳米颗粒的远程组装
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US20150209273A1 (en) * 2012-08-28 2015-07-30 Glaxosmithkline Llc Pharmaceutical Compositions
CN108619161A (zh) * 2013-03-15 2018-10-09 加利福尼亚大学董事会 无环核苷膦酸二酯
CN111777639A (zh) 2013-11-15 2020-10-16 奇默里克斯公司 十六烷氧基丙基膦酸酯的形态
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
BR112016020233B1 (pt) 2014-03-14 2022-07-19 Alltech Inc. Composições de compostos seleno orgânicos e seus usos
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
EA036391B1 (ru) 2014-09-15 2020-11-05 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Нуклеотидные аналоги
EP3212656B1 (en) 2014-10-27 2019-06-05 Concert Pharmaceuticals Inc. Pyrimidine phosphonic acid esters bearing at least one deuterium atom
EP3288547B1 (en) * 2015-04-27 2023-06-07 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
RU2628456C1 (ru) * 2016-06-29 2017-08-17 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Новые пиримидиновые ингибиторы репликации аденовируса человека
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
RU2670204C1 (ru) * 2017-12-01 2018-10-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-тиоурацила, обладающие противоаденовирусной активностью
EP3730503A4 (en) * 2017-12-21 2021-05-05 Shenzhen TargetRx, Inc. ANTIVIRAL REVERSE TRANSCRIPTASE INHIBITOR
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4200301A1 (en) 2020-08-24 2023-06-28 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) * 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
DE2009341C3 (de) 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
FR2586685B1 (fr) * 1985-09-03 1987-12-11 Protex Manuf Prod Chimiq Procede de preparation de nouveaux agents dispersants cationiques
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
JPH05339280A (ja) * 1991-04-26 1993-12-21 Japan Tobacco Inc （ｎ−二環置換）アミノメチレンビスフォスフォン酸誘導体
JP3341303B2 (ja) * 1991-07-11 2002-11-05 東レ株式会社 メチレンジホスホン酸誘導体、その製造方法およびその医薬用途
US5879700A (en) 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
US5618804A (en) 1992-07-10 1997-04-08 Toray Industries, Inc. Methanediphosphonic acid derivative, process for production thereof and use for pharmaceuticals
JP3580377B2 (ja) * 1993-06-29 2004-10-20 三菱化学株式会社 ホスホナートヌクレオチドエステル誘導体
CA2126601A1 (en) * 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
CH690163A5 (fr) 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
WO1998026749A1 (fr) * 1996-12-19 1998-06-25 Kao Corporation Composition de revetement pour les dents
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
JP2001515039A (ja) * 1997-08-18 2001-09-18 クイーンズ ユニバーシティ アット キングストン アミロイド症を治療するためのホスホノ−カルボキシレート化合物
FR2781228B1 (fr) * 1998-07-16 2000-09-29 Pf Medicament Phosphonates insatures derives d'indole
CA2747954C (en) * 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds

Also Published As

Publication number Publication date
EP1233770A4 (en) 2003-04-16
MXPA02005490A (es) 2004-09-10
CN1414854A (zh) 2003-04-30
US9206208B2 (en) 2015-12-08
JP5963787B2 (ja) 2016-08-03
US8889658B2 (en) 2014-11-18
US20040127735A1 (en) 2004-07-01
PT1233770E (pt) 2008-04-24
US8309565B2 (en) 2012-11-13
PT1914237E (pt) 2014-09-09
ATE385797T1 (de) 2008-03-15
JP2014074065A (ja) 2014-04-24
CN1414854B (zh) 2015-08-19
ES2498046T3 (es) 2014-09-24
JP4993649B2 (ja) 2012-08-08
DE60038038D1 (en) 2008-03-27
US7452898B2 (en) 2008-11-18
AU2006252074B2 (en) 2010-09-30
US7790703B2 (en) 2010-09-07
RU2258707C2 (ru) 2005-08-20
ES2300281T3 (es) 2008-06-16
BR0016058A (pt) 2003-07-15
US8008308B2 (en) 2011-08-30
US20100173870A1 (en) 2010-07-08
US8710030B2 (en) 2014-04-29
US20140045794A1 (en) 2014-02-13
DK1914237T3 (da) 2014-09-15
CA2393410C (en) 2011-10-11
US7094772B2 (en) 2006-08-22
US7098197B2 (en) 2006-08-29
WO2001039724A3 (en) 2001-10-18
US20050182019A1 (en) 2005-08-18
US6716825B2 (en) 2004-04-06
US20050176673A1 (en) 2005-08-11
AU785355B2 (en) 2007-02-01
CA2393410A1 (en) 2001-06-07
JP2004500352A (ja) 2004-01-08
US20170239279A1 (en) 2017-08-24
US20150051174A1 (en) 2015-02-19
CY1107927T1 (el) 2013-09-04
AU2010257309B2 (en) 2014-04-10
JP5963894B2 (ja) 2016-08-03
US20160067268A1 (en) 2016-03-10
US7687480B2 (en) 2010-03-30
JP2011246475A (ja) 2011-12-08
HK1050627B (zh) 2008-12-24
DE60038038T2 (de) 2009-02-12
US10071110B2 (en) 2018-09-11
EP1233770A2 (en) 2002-08-28
EP1233770B1 (en) 2008-02-13
AU2006252074A1 (en) 2007-01-18
US7034014B2 (en) 2006-04-25
US20120058975A1 (en) 2012-03-08
AU2010257309A1 (en) 2011-01-13
US20130045950A1 (en) 2013-02-21
AU1949701A (en) 2001-06-12
WO2001039724A2 (en) 2001-06-07
CA2747954C (en) 2014-02-25
JP2015078230A (ja) 2015-04-23
US9649321B2 (en) 2017-05-16
CA2747954A1 (en) 2001-06-07
US20040019232A1 (en) 2004-01-29
US20070161602A1 (en) 2007-07-12
HK1050627A1 (en) 2003-07-04
KR20020073342A (ko) 2002-09-23
US20060281706A1 (en) 2006-12-14
US20080103115A1 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
ATE385797T1 (de) Phosphonatverbindungen
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
HK1050899A1 (en) Pteridine compounds for the treatment of psoriasis
SE0200920D0 (sv) Novel compounds
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BRPI9917739B8 (pt) composto intermediário na preparação de inibidores de cox-2
CY1109422T1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
SE0104140D0 (sv) Novel Compounds
EP0911321A3 (en) Compounds for the treatment of osteoporosis
SE9901272D0 (sv) New improved formulation
MY128924A (en) Novel compounds
AP9801269A0 (en) Prostaglandin agonists.
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
EE200200208A (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
DE60112330D1 (en) Pyrazolopyridinderivate
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
BR9808923A (pt) Composto, e, processo para fazer o mesmo
SE0202693D0 (sv) Compounds
DE60201074D1 (en) Pyrazolopyridinderivate
MXPA02001204A (es) Compuestos calciliticos.